North America Cancer Biopsy Market Size To Worth USD 26.78 Billion By 2033 | CAGR of 10.1%
Category: HealthcareNorth America Cancer Biopsy Market Size To Worth USD 26.78 Billion By 2033
According to a research report published by Spherical Insights & Consulting, the North America Cancer Biopsy Market Size is to Grow from USD 10.23 Billion in 2023 to USD 26.78 Billion by 2033, at a Compound Annual Growth Rate (CAGR) of 10.1% during the projected period.
Get more details on this report -
Browse key industry insights spread across 210 pages with 101 Market data tables and figures & charts from the report on the "North America Cancer Biopsy Market Size, Share, and COVID-19 Impact Analysis, By Product (Instruments, Kits and Consumables, and Services), By Type (Tissue Biopsy, Surgical Biopsy, Liquid Biopsy, and Others), and North America Cancer Biopsy Market Insights, Industry Trend, Forecasts to 2033." Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/north-america-cancer-biopsy-market
Cancer biopsy is the term used to describe the procedures and methods used to find out whether a person has cancer. A cancer biopsy's objective is to find anomalies in tissues or cells that might point to the emergence of malignant growths. Numerous techniques are included in these diagnostic tools, such as molecular analysis, laboratory testing, and medical imaging. A cancer biopsy is essential to the overall treatment of cancer because it allows for prompt interventions and improves patient outcomes. Given the rising incidence of cancer, accurate diagnostics are desperately needed to enable prompt and accurate detection, which will enable the implementation of suitable treatment plans. The market for cancer biopsies in North America is anticipated to develop significantly due to the rise in cancer cases, as researchers and healthcare professionals look for novel ways to enhance early diagnosis, prognosis, and treatment results in the face of a growing health crisis. However, new cancer diagnostic technology adoption in North America may be hampered by concerns and misinformation.
The kits and consumables segment is anticipated to hold the largest market share of the North America Cancer Biopsy market during the projected timeframe.
Based on the product, the North America Cancer Biopsy market is divided into instruments, kits and consumables, and services. Among these, the kits and consumables segment is anticipated to hold the largest market share of the North America Cancer Biopsy market during the projected timeframe. The collection and analysis of tissue samples, which leads to an accurate diagnosis of cancer, requires biopsy kits and consumables including needles and reagents. The expansion of the market has been greatly aided by large expenditures made by prominent industry participants.
The liquid biopsy segment is anticipated to dominate the North America Cancer Biopsy market during the projected timeframe.
Based on the type, the North America Cancer Biopsy market is classified into tissue biopsy, surgical biopsy, liquid biopsy, and others. Among these, the liquid biopsy segment is anticipated to dominate the North America Cancer Biopsy market during the projected timeframe. The usage and market share of liquid biopsy have grown dramatically because of its advantages, which include reduced costs, early prognosis, therapy monitoring, and patient comfort. Clinical oncology has been revolutionized by liquid biopsies, which provide a minimally invasive approach to tumor identification, screening, recurrence early detection, and customized treatment plans.
Major vendors in the North America Cancer Biopsy market include Illumina Inc., BD (Becton, Dickinson, and Company), Myriad Genetics Inc., Thermo Fisher Scientific, BIOCEPT INC., Hologic Inc., Danaher, Agilent Technologies Inc., IZI Medical, Johnson & Johnson Services, Inc., Medtronic, Boston Scientific Corporation, VESICA HEALTH, INC., CONMED Corporation, INRAD, Inc., and Others.
Recent Developments
- In May 2024, The AssureMDx test was developed in a lab and introduced by VESICA HEALTH, INC., a liquid biopsy firm that specialized in the treatment of hematuria and the early identification of bladder cancer. AssureMDx, which offered remarkable accuracy and dependability based on substantial scientific validation, was a breakthrough in bladder cancer diagnoses. Vesica Health's constant dedication to improving the care of hematuria patients globally was demonstrated by this innovative test.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Market Segment
This study forecasts revenue at North America, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the North America Cancer Biopsy market based on the below-mentioned segments:
North America Cancer Biopsy Market, By Product
- Instruments
- Kits and Consumables
- Services
North America Cancer Biopsy Market, By Type
- Tissue Biopsy
- Surgical Biopsy
- Liquid Biopsy
- Others
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm that provides actionable market research study, quantitative forecasting, and trends analysis provides forward-looking insight especially designed for decision-makers and aids ROI.
Which caters to different industries such as financial sectors, industrial sectors, government organizations, universities, non-profits, and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?